Reversal of Lipid-Induced Insulin Resistance

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Behavioral
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The purpose of this study is to examine whether weight reduction decreases intramyocellular (IMCL) and hepatic lipid content, and improves insulin sensitivity of muscle and fat tissue in people who are insulin resistant and have a family history of type 2 diabetes. Hepatic mitochondrial oxidation will be assesses using a 3 hour triple tracer study (D7 glucose, 3-13C lactate and 13C4 beta-hydroxybutyrate).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 90
Healthy Volunteers: t
View:

• Healthy, sedentary, non-smoking and not taking any medications other than birth control pills.

• Hematocrit \>35%

• Subjects will have no systemic or organ disease including diabetes.

• Subjects will have no history eating disorders.

• Women must be using a form of birth control (sexual abstinence, birth control pills, Norplant, IUD or condoms) and will be studied between day 0 and 7 of their menstrual cycle.

• Those who are taking birth control pills or have had a hysterectomy may be studied at any time.

• Physical activity will be assessed using a standard questionnaire with an activity index cut off at 2.3.

Locations
United States
Connecticut
Magnetic Resonance Research Center (MRRC)
ENROLLING_BY_INVITATION
New Haven
Yale Center for Clinical Investigation HRU
RECRUITING
New Haven
Contact Information
Primary
Kitt Petersen, MD
kitt.petersen@yale.edu
203-785-5447
Time Frame
Start Date: 2002-10
Estimated Completion Date: 2034-12
Participants
Target number of participants: 250
Treatments
Experimental: Lifestyle Intervention
Caloric Restriction to reverse lipid-induced insulin resistance.
Experimental: Baseline Assessment of Hepatic Mitochondrial Fat Oxidation
Tracer study to assess hepatic mitochondrial fat oxidation (PINTA).
Related Therapeutic Areas
Sponsors
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Leads: Yale University

This content was sourced from clinicaltrials.gov